We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Nov 20 Best Practices IV: Preclinical Outsourcing Program/Simulcast

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Nov 20 Best Practices IV: Preclinical Outsourcing Program/Simulcast"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The BioPharma Research Council (BRC) will present its Best Practices IV: Preclinical Outsourcing, November 20, 2013 (12:30-4 pm EST), at the Conference Center at Ocean Place in Long Branch, NJ, and via Webinar.

The program will evaluate the effective use of contract research organizations (CROs) by academia, industry and nonprofit entities to develop innovative therapeutics.

"As biopharmaceuticals have developed into a 50 billion dollar a year industry, preclinical outsourcing has become a common practice," says Program Director Dolly Koltchev, PhD. "Companies have become reliant on outside, specialized services to supplement their internal research and development.

"Our speakers will present their most effective practices in preclinical outsourcing for feeding drug development pipelines, and building strong relationships that lead to advancements in curing human disease."

The scheduled presenters will provide thoughtful insight into current industry trends, as well as ideas for increasing efficiency and productivity in the preclinical process.

Utilizing modern technology to cut both the costs and risks of preclinical research are underlying themes.

Among the presenters are Rachel Lane, Ph.D., Assistant Director, Scientific Affairs, at
Alzheimer's Drug Discovery Foundation (ADDF); Kuldip Dave, Ph.D., Senior Associate Director, Research Programs, at The Michael J. Fox Foundation for Parkinson's Research (MJFF); Patrick M. Dentinger, President & CEO, Absorption Systems; and Christopher J. Kemper, Ph.D., Principal, PharmaNavigators, LLC.